FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC with High c-Met Protein Overexpression By Ogkologos - June 13, 2025 573 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LUMINOSITY study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Many Men with Penile Cancer Do Not Get Recommended Treatments, Study... March 22, 2018 Common Questions About COVID-19 and Cancer: Answers for Patients and Survivors June 25, 2020 MAP Congress 2020: Molecular Analysis for Precision Oncology October 2, 2020 Emergency presentations: what are they, and what do they mean for... April 7, 2022 Load more HOT NEWS SIOG 2020: New Research in Caring for and Treating People With... New reports show staff shortages continue to hold back cancer care Conducting Phase I Clinical Trials During the COVID-19 Pandemic 120 years of discovery: 10 ways we’ve changed the story for...
